Mark J. Ratain to Suramin
This is a "connection" page, showing publications Mark J. Ratain has written about Suramin.
Connection Strength
1.266
-
A phase I study of suramin with once- or twice-monthly dosing in patients with advanced cancer. Cancer Chemother Pharmacol. 2002 Jul; 50(1):1-5.
Score: 0.216
-
Evaluation of neuropathy in patients on suramin treatment. Muscle Nerve. 1997 Jan; 20(1):83-91.
Score: 0.149
-
Mineralocorticoid insufficiency due to suramin therapy. Cancer. 1996 Dec 01; 78(11):2411-20.
Score: 0.148
-
Phase I study of suramin administered by intermittent infusion without adaptive control to cancer patients: update of two expanded dose levels near the maximally tolerated dose. J Clin Oncol. 1996 Sep; 14(9):2622-3.
Score: 0.146
-
Data modifications to phase I study of suramin. J Clin Oncol. 1996 Sep; 14(9):2623-4.
Score: 0.146
-
Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer. J Clin Oncol. 1995 Sep; 13(9):2196-207.
Score: 0.136
-
Suramin: is adaptive control necessary? J Clin Oncol. 1992 Dec; 10(12):1984-5; author reply 1985-6.
Score: 0.112
-
Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480. Cancer. 2004 Nov 15; 101(10):2202-8.
Score: 0.064
-
A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma. Cancer. 2004 Jan 01; 100(1):65-71.
Score: 0.060
-
Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480. J Clin Oncol. 2002 Aug 15; 20(16):3369-75.
Score: 0.055
-
Keratoacanthomas and skin neoplasms associated with suramin therapy. Arch Dermatol. 1996 Jan; 132(1):96-8.
Score: 0.035